Next Generation Monoclonals Less Profitable than Trailblazers ?  

Oleh:

Mitchell, Peter

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 8 (Agu. 2005), page 906.
Topik: monoclonal; monoclonals; profitable; trailblazers

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.4 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

A new study has suggested that therapeutics based on monoclonal antibodies (mAbs) are far more likely to be commercially successful than their small molecule predecessors. For the next generation of mAb involved biotech companies, it may not be as easy as before to sustain that trend. Although mAbs have been successfull so far, the competition among the new crop of mAbs and from other types of biological products is likely to intensify, especially in fields like oncology. According to a study completed in june 2005 by london based consultancy propagate pharma, about half the mAbs launched so far appear to be profitable...

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali